Calgary, Canada
Calgary, Canada

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that focuses on the development of pharmaceutical products for the treatment of human cancers. The product Reolysin harnesses the oncolytic capabilities of naturally-occurring reovirus , which has been shown to replicate specifically in cells with an activated Ras pathway. Ras pathway mutations are found in approximately two thirds of all tumours, including most metastatic disease, which makes Reolysin a potential therapeutic for cancer. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Oncolytics Biotech | Date: 2015-04-23

Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.


Patent
Oncolytics Biotech | Date: 2015-04-22

Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.


Patent
Oncolytics Biotech | Date: 2013-05-28

The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.


Patent
Oncolytics Biotech | Date: 2015-12-09

The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.


Patent
Oncolytics Biotech | Date: 2014-02-13

The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.


The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.


Patent
Oncolytics Biotech | Date: 2014-02-07

The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.


Patent
Oncolytics Biotech | Date: 2014-11-12

Provided herein is a method of treating cancer in a subject. The method includes administering to the subject an oncolytic virus and an increased treatment regimen of a chemotherapeutic agent, wherein administration treats the cancer in the subject. Also provided is a kit comprising an oncolytic virus and a chemotherapeutic agent, wherein the chemotherapeutic agent comprises an amount for an increased treatment regimen of a chemotherapeutic agent.


Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.


Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.

Loading Oncolytics Biotech collaborators
Loading Oncolytics Biotech collaborators